BioProcess Insider's Editor in Chief sat down with biopharmaceutical inudstry experts to reflect on how the quarterly movements of the wider pharma industry are affecting the biomanufacturing space

BPI Staff

September 29, 2021

20 Min View
BioProcess Insider State of the Industry — September 2021 Panel Discussion

Date: Sep 29, 2021

Duration: 20 Min

Our BioProcess Insider editorial team sits down with Joshua Speidel, PhD Partner, Latham Biopharm Group, Patrick Lucy, President and CEO, Lykan Biosciences, and Amélie Boulais, Head of Market Entry Strategy, Virus Based Therapeutics at Sartorius, to reflect on how the quarterly movements of the wider pharma industry are affecting the biomanufacturing space. Through the analysis of global events, recent deal making, and regulatory and technological advancements, we look to determine the factors driving or squeezing production and pre-empt upcoming trends and concerns facing our sector.

You May Also Like